Categories
How do you budget for healthcare market research? Start with the business decision, then assess feasibility, methods, and data value.
In pharmaceutical and medical device market research, the people you need to reach drive most of a study's cost. What the business does with those people's answers determines the study's return.
Healthcare market research budgets draw scrutiny early, often before anyone agrees on the questions. Procurement pushes the price. The brand team wonders whether a cheaper study would do the job. The insights lead defends a number before anyone ties it to a decision. Cost per complete dominates those conversations, but it shouldn't lead them. Start with a harder question: Will this study produce evidence strong enough to carry the decision behind it?
Price alone won't answer that. A cheap study that leaves the team's question open saves the business nothing, because someone will fund a second study to close the question. A bigger study can miss the other way, with sample and segments no one plans to use. To validate a budget, measure how well the investment fits the decision and the evidence that decision demands.
Work through these questions with your team and your research partner:
When the team can answer each of those clearly, the budget conversation becomes much more meaningful.
Every completed survey or interview represents a physician who made time between patients, a caregiver who answered at the end of a long day, or a patient who described life with a condition. A healthcare study buys their time above all else. A budget validated against the decision puts that time to good use.
Start with the decision the research informs. Research projects lose value fastest when they begin with the methodology rather than the problem. A team may already know it wants an awareness, trial, and usage study, or 30 in-depth interviews with oncologists. Before that plan becomes a proposal, take a step back. Which decision will this research inform? Who will make it, and by when? Every question on the survey or discussion guide should trace back to those answers and why you need them in the first place.
Just as important, look for any question the decision needs answered that nobody thought to ask. The cheapest cut available happens on paper: Drop any question that doesn't serve the decision, for sure, but the missing question can cost more. When it surfaces after fieldwork, it usually sends the team back into the field.
Most of the cost comes down to who you need to reach. Specialists take more work to schedule than primary care physicians. Patients with a rare condition take longer to find and screen than a broad population. Honoraria must reflect fair market value for a clinician's time. Geography, quotas, questionnaire length, and timeline add to all of it.
Each of those costs deserves a look, and one test applies to all of them: Does the decision depend on it? Hard-to-reach respondents earn their cost when their answers carry the decision. Tighter quotas and a larger sample make sense when the business plans to act differently by segment. If no one intends to act on the split, the extra sample only adds expense.
Ask your fieldwork partner how it arrived at its incidence and feasibility estimates. Incidence — the share of screened respondents who qualify for a study — sets how much recruiting the study will need. When a proposal rests its price on optimistic incidence, it tends to go one of three ways: over budget, past the deadline, or loose on screening criteria to make quota. The partner's answer will tell you a lot about whether the budget holds up.
Choose the method that delivers the level of evidence the decision needs. To size a market or track awareness, you need scale. To understand why prescribers hesitate to switch therapies, you need depth. Some decisions need both scale and depth. Many don't.
But be cautious: an overly simple approach creates false economies when the data come back too weak to support action. An unnecessarily complex design errs the other way and adds cost that's never validated by the decision at hand.
In healthcare samples, the budget pays to confirm each respondent's identity, down to credentials, specialty, or diagnosis. Weak verification puts the whole dataset at risk. Ask what verification the proposal includes and what you would risk without it. This single data point serves as an important value proposition to those scrutinizing your research spend.
Design it for reuse before fieldwork starts. Good research shouldn't become obsolete the moment the project ends. A study you field before launch can become the baseline for a tracker. Analysts can recut segments as medical affairs or market access teams bring new questions. You can return to respondents who gave recontact permission and ask questions again after launch to see what changed.
Teams build most of that value in before the fieldwork: consistent question wording for future waves, permission from respondents to recontact them, and a data structure other teams can use. Those pieces cost little up front. Once fieldwork closes, you may not get them at all. When the people you need prove difficult to reach, reuse lets the organization get more than one answer from the effort it took to hear from them.
Map each likely result to a next step before you approve the spend. Ultimately, research earns its value through what the organization does with what it learned. If every plausible finding leads to the same decision, the study needs another look. It may not need to run at all.
Expect a partner that challenges the design before it prices it. A strong partner shouldn't simply take a client's initial research request and translate it into a proposal. Recruitment and fieldwork teams see a study's full design early, and they usually know which parts will cause trouble in the field. Look for a partner that will tell you when an incidence estimate looks optimistic or a quota will stretch the timeline; you want a partner that will recommend a simpler design when it can answer the question. Sometimes an honest partner recommends a bigger investment, because the current design can't produce data the business can act on. Those conversations cost the least before anyone approves the budget.
Cost per complete divides a study's field cost by the number of qualified respondents who finish it. It offers a quick way to compare proposals, but it can't tell you whether the study will answer the business question. Pair it with a check on the decision the research supports.
Physicians, especially specialists, make up a small and busy population. Recruiters need more outreach to find qualified respondents, honoraria must reflect fair market value for a clinician's time, and verification adds another step. Rare specialties and low-incidence patient populations raise costs further.
Incidence rate measures the share of screened people who qualify for a study. Low incidence forces recruiters to screen more people to fill each quota, which adds time and cost. Optimistic incidence estimates often lead to budget overruns, missed deadlines, or loosened screening criteria.
Cut questions that don't serve the decision, drop segments no one plans to act on, and match sample size to the precision the decision requires. Keep respondent verification in place, since weak verification puts the entire dataset at risk.
Comments
Comments are moderated to ensure respect towards the author and to prevent spam or self-promotion. Your comment may be edited, rejected, or approved based on these criteria. By commenting, you accept these terms and take responsibility for your contributions.
Disclaimer
The views, opinions, data, and methodologies expressed above are those of the contributor(s) and do not necessarily reflect or represent the official policies, positions, or beliefs of Greenbook.
More from Isaac Rogers
2 min read
Technology dominated this year’s GRIT report, but if you skimmed over “skills emphasized for staff development,” you might miss that the leaders in te...
3 min read
When embracing new ideas and innovation for the future, organizations also need to take stock of what needs to be stopped in the present.
ARTICLES
What drives GLP-1 adoption? Explore how awareness, trust, access, and physician influence shape consumer readiness in the U.S. and India.
Explore AI in health and life sciences research, from knowledge retrieval and AI personas to trusted...
6 min read
Both researcher and ALS patient, Cecil reveals how data quality, trust, and transparency shape real outcomes in today’s healthcare systems.
The Greenbook Podcast
Discover how Val Pastrana brings consumer-centricity to pharma innovation. Learn about AI in research, future-back innovation, and leadership in insig...
Sign Up for
Updates
Get content that matters, written by top insights industry experts, delivered right to your inbox.